WuXi XDC Cayman Inc
2268
Rangering i aksjer
#1886
WuXi XDC Cayman Inc. operates as an investment holding company and a global... WuXi XDC Cayman Inc. operates as an investment holding company and a global contract research, development, and manufacturing organization (CRDMO), with operations spanning China, North America, Europe, and other international regions. The company's expertise covers the entire lifecycle, from discovery and research to development and manufacturing, of biopharmaceutical products. Specifically, it focuses on antibody-drug conjugates (ADCs), various bioconjugates, monoclonal antibody intermediates, and the crucial payload-linkers integral to bioconjugate synthesis. Founded in 2013 and headquartered in Wuxi, China, WuXi XDC Cayman Inc. is a subsidiary of WuXi Biologics (Cayman) Inc.
Aksjekurs
$8.78
Markedsverdi
$11.12B
Endring (1 dag)
-9.52%
Endring (1 år)
0.57%
Land
CN
Handel WuXi XDC Cayman Inc (2268)
Kategori
Healthcare
P/B-forhold for WuXi XDC Cayman Inc (2268)
P/B-forhold per October 2026 TTM: 6.53
Ifølge WuXi XDC Cayman Inc sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 6.53. Ved slutten av 2024 hadde selskapet et P/B-forhold på 5.20.
P/B-historikk for WuXi XDC Cayman Inc fra 2020 til 2026
P/B-forhold ved hvert års slutt
| År | P/B-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 6.53 | -2.87% |
| 2025 | 6.72 | 29.37% |
| 2024 | 5.20 | -10.37% |
| 2023 | 5.80 | -70.54% |
| 2022 | 19.68 | -98.47% |
| 2021 | 1.29K | 1,641.63% |
| 2020 | 73.89 | 0.00% |
P/B-forhold for lignende selskaper eller konkurrenter
| Selskap | P/B-forhold | Forskjell i P/B-forhold | Land |
|---|---|---|---|
| 4.7411 | -27.36% |
US
|
|
| 3.0143 | -53.82% |
US
|
|
| 31.051 | 375.74% |
US
|
|
| 4.9326 | -24.43% |
CN
|
|
| 6.8081 | 4.31% |
US
|
